Articles On Noxopharm (ASX:NOX)

Its partnership with Hudson Institute of Medical Research, NOX has also led to an important discovery about the anti-inflammatory mechanism of action of idronoxil, the active ingredient in Veyonda®.

The Noxopharm Ltd (ASX: NOX) share price has been a strong performer on Monday. The clinical-stage drug development company’s shares were up as much as 13% to 63 cents at one stage today. The Noxopharm share price has since pulled back and...

IDT Australia (ASX:IDT) jumped more than 20% after announcing that it has formalised activities with the Australian Government to potentially assist with the production of a COVID-19 vaccine. There was recent media interest surrounding a mR...

Another red day for the ASX to close out the week. The ASX 200 closed 0.05% down from yesterday at 7,461 points, 2.2% lower than a week ago. The ASX Emerging Companies Index meanwhile dropped 2.09%, closing at 2,187 points which is over 5%...

The broader ASX continued its losing streak, shedding another 0.5% while the benchmark ASX 200 closed at 7,465 points, which is 2.2% lower than last Friday’s close. Health and consumer discretionary goods were rays of sunshine with gains of...

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

The clinical-stage drug development company’s collaboration with the US National Cancer Institute will run for an initial 12-month term, with the subsequent brain cancer program supported by a fully-costed budget.

Clinical-stage drug development company Noxopharm (ASX:NOX) has announced a formal collaboration with the National Cancer Institute within the US National Institutes of Health in the quest for more effective treatments of brain canc...

The clinical-stage drug development company will team up with an arm of the National Institutes of Health as it investigates a new family of anti-cancer drugs.

Wall Street mixed despite blowout jobs numbers US stock market were mixed on Friday, despite stronger than expected employments figures in the US. The Dow Jones rose by 0.41%, S&P 500 by 0.17% – both closing at record highs – while tech...

The S&P/ASX200 closed up Thursday, gaining 7.90 points or 0.11% to 7,511.10 and setting a new 100-day high. The top performing stocks in this index were NIB Holdings Limited (ASX:NHF)  Nuix Limited (ASX:NXL), up 3.05% and 2.75% respecti...

It now sees Veyonda having a major commercial future in the rapidly growing field of radioligand therapy, not just in prostate cancer, but across the broad cancer spectrum. 

ASX 200 health stocks index (XHJ) rose by 0.23% this morning, compared to the broader index which rose by 0.11%. Micro cap medical device company dorsaVi (ASX:DVL) took the limelight this morning, jumping by 12% after saying that it has ext...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

IRIS Metals is set to become the latest Kookynie entrant to join the ASX boards, with its sights set on following the recent exploration successes other companies have had in the Kookynie mining camp. The company’s portfolio includes teneme...

Noxopharm is studying its Veyonda® drug candidate across a wide range of medical disciplines, with activity pursued across its oncology, COVID-19, septic shock, chronic inflammatory and autoimmune diseases portfolio.

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

It has an exciting pipeline of drugs under development and believes its novel technology platform is “one of the most exciting and valuable platforms” in the pharmaceutical industry.

With a key regulatory approval in place, Noxopharm is a step closer to starting a multi-national trial on patients with progressive, metastatic prostate, breast or lung cancers using a higher dose of its Veyonda® drug candidate.

Australian clinical-stage drug development company Noxopharm (ASX:NOX) has announced that the US FDA has granted Investigational New Drug approval to the DARRT-2 study.

The clinical-stage drug development company believes, if a patent is granted, it will support its ambition to make Veyonda a standard of care drug in combination with major cancer therapies.

Shares in Noxopharm Ltd (ASX: NOX) are gaining today following the company’s announcement of a notice of allowance for an important European patent. At the time of writing, the Noxopharm share price is 64 cents – 7.56% higher than its prev...

The Phase Two trial will broaden the scope of studies into a potential cancer treatment using a higher dose of its Veyonda® drug candidate.

The Noxopharm Ltd (ASX: NOX) share price is falling this afternoon. This comes after the company released an update about its DARRT-2 clinical trial. At the time of writing, Noxopharm shares are swapping hands for 69 cents apiece, down 1.4...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

The company is more than one drug – the business is a drug pipeline based on a novel technology platform that it sees meeting a range of unmet needs of key current interest to the global pharmaceutical industry.

Summary The S&P/ASX200 is trading 5.20 points higher to 7265.30 by the afternoon. The index scaled a new intra-day high of 7282.3, before easing back. Healthcare, Industrials and Consumer Staples stocks gained over 1% each. ...

Noxopharm welcomes this outcome given its recent LuPIN trial data showing even stronger survival outcome when Lu-PSMA-617 is combined with Veyonda®.

The Noxopharm Ltd (ASX: NOX) share price is on course to end the week on a positive note. In morning trade, the clinical-stage drug development company’s shares are up 3% to 72 cents. This means the Noxopharm share price now up over 50% sin...

Summary The ASX 200 closed lower by 19 points or 0.27% at 7142.60. The Australian dollar and bond yields rise after the RBA policy decision. The RBA kept interest rates steady at record lows to support the economic growth. Austral...

The Noxopharm Ltd (ASX: NOX) share price went gangbusters today after the company released a new report about its flagship drug, Veyonda. Shares in the biotech closed trade 22% higher at 74 cents a share. Lets take a closer look at what pr...

ShareCafeAustralia…1 hour in… ASX200 up 3 ASX200 up 3 points to 7182.   A2Milk (-0.5%); said it is aware of media reporting concerning a potential class action against them that is apparently being investigated by Slater & Gordon Lawye...

Wall Street higher as Biden proposed US$6 trillion budget All major indices rose on Friday, as US President Biden proposed a US$6 trillion budget spending for 2022, the highest US federal spend since WW2. The Dow Jones rose by 0.19%, S&...

It was a good day for some of ASX-listed cancer therapy stocks yesterday, with three companies releasing seperate announcements that sent their share prices higher. Cancer therapy stocks Invion (ASX:IVX), Immutep (ASX:IMM), and Imugene (ASX...

ShareCafeNoxopharm (ASX: NOX) – Webinar Presentation Presenter – Graham Kelly – CEO & MD – Noxopharm is a clinical stage drug development company. Noxopharm (ASX: NOX) – Webinar PresentationCompany News

ShareCafeHidden Gems Webinar Recap – LAU, NOX, TZL, ANP, VMS Catch up on the full webinar with presentations from  Antisense Therapeutics (ASX: ANP), Lindsay Australia (ASX: LAU), Noxopharm (ASX: NOX), Venture Minerals (ASX: VMS) & TZ...

In Part 1 of the study, an 1800 milligram dose of Veyonda® was determined to be well tolerated in patients with compromised lung function.

Summary The WCN share price has closed up by 17.6%, as the company announced assay results. QuickFee has seen a remarkable increase in lending activity in Australia. The DRE share price has risen by 8.7% to AU$0.025 in today’s session...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday trade. WINNERS Scrol...

The ASX 200 has rebounded from yesterday’s loss though the technology sector has weighed on the market for two consecutive weeks. The index closed 0.20 per cent higher, and is also up by 0.70 per cent for the week. IT slumped by another 2.5...

Noxopharm Ltd (ASX: NOX) shares are having a bumper end to the week after the company released a market update this morning. At the time of writing, the Noxopharm share price is storming 16.49% higher to 56.5 cents. In earlier trade, the c...

CEP-2 will build on the encouraging outcomes of the CEP-1 pilot study where the chemo-enhancing effect of Veyonda was used to lower dosages of chemotherapy in patients with advanced solid cancers.

Dow Jones and iron ore reset records The Dow Jones index rose again overnight by 0.93%, resetting the record highs it set the previous day. Other major US indices also rose, after jobless claims in the US came in less than expected. S&P...

The aim of the CEP-1 study is to show that Veyonda boosts the effectiveness of conventional chemotherapy to allow the use of lower, safer dosages of chemotherapy.

Summary Drug discovery company developing new therapies, Dimerix, has enrolled multiple patients in REMAP-CAP study in Europe. In the ACE2 RAS study domain, subjects will be randomised to receive one RAS blockade strategy or control....

The data supports the international patent application lodged on 30 March 2021, making the provisional patent a potentially very valuable commercial asset.

The data supports the international patent application lodged on 30 March 2021, making the provisional patent a potentially very valuable commercial asset.